RespireRx Pharmaceuticals Inc. Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea
November 30, 2017 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Nov. 30, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”) announces that the results of the PACE (Pharmacotherapy of Apnea by...